Everett Harris & Co’s Moderna MRNA Stock Holding History

Everett Harris & Co’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$462K	Hold	6,600	–	–	0.01%	214
2026 Q1	$335K	Buy	+6,600	New	+$308K	﹤0.01%	260
2025 Q1	–	Sell	-6,602	Closed	-$275K	–	322
2024 Q4	$275K	Buy	+6,602	New	+$316K	﹤0.01%	254

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Everett Harris & Co's MRNA Position: Q2 2026 in Review

Everett Harris & Co held its Moderna (MRNA) position steady in Q2 2026 at 6,600 shares worth $462K. The position accounts for 0.01% of the portfolio, ranked #214.

Everett Harris & Co first reported a position in MRNA in Q4 2024 and has held it in 3 quarters since. 777 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

Everett Harris & Co held 6,600 shares of Moderna worth $462K as of Q2 2026.
Everett Harris & Co left its Moderna share count unchanged in Q2 2026.
Moderna made up 0.01% of Everett Harris & Co's portfolio in Q2 2026, its #214 holding.
Everett Harris & Co first reported a position in Moderna in Q4 2024 and has held it in 3 quarters since.
777 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Everett Harris & Co's 13F filing for Q2 2026, filed 3 Aug 2026.